OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
Chiltern and Ockham announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
Chiltern and Ockham, two full-service contract research organizations (CROs), announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
The combined company will be called Chiltern. Ockham’s management team will join the management of the enlarged group. Chiltern’s CEO Jim Esinhart, PhD will be CEO of the Chiltern Group, with Ockham’s CEO, James V. Baker, becoming Chief Development Officer. Nick Thornton will remain as Chairman.
The merged entity combines service offerings in three areas: oncology; services and FSP/Sourcing
Read the full release here.